105 related articles for article (PubMed ID: 15878795)
1. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
2. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract][Full Text] [Related]
4. LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201.
Wang J; Krishnamoorthi V; Wang E; Yang C; Baptista D; Wu X; Liu M; Gardner M; Elkins P; Hines J; Liu P
J Pharm Biomed Anal; 2010 Mar; 51(4):824-33. PubMed ID: 19897331
[TBL] [Abstract][Full Text] [Related]
5. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
6. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
7. A new generation of bradykinin antagonists.
Stewart JM; Gera L; Hanson W; Zuzack JS; Burkard M; McCullough R; Whalley ET
Immunopharmacology; 1996 Jun; 33(1-3):51-60. PubMed ID: 8856115
[TBL] [Abstract][Full Text] [Related]
8. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
9. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract][Full Text] [Related]
10. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro antitumor effect of a unique nutrient mixture on lung cancer cell line A-549.
Waheed Roomi M; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Exp Lung Res; 2006 Oct; 32(9):441-53. PubMed ID: 17162651
[TBL] [Abstract][Full Text] [Related]
12. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
13. A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Galoppini C; Meini S; Tancredi M; Di Fenza A; Triolo A; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mazzucco S; Papini A; Rovero P
J Med Chem; 1999 Feb; 42(3):409-14. PubMed ID: 9986712
[TBL] [Abstract][Full Text] [Related]
14. An NMR conformational analysis of cyclic bradykinin mimics. Evidence for a beta-turn.
Miskolzie M; Yamamoto H; York EJ; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2000 Jun; 17(6):947-55. PubMed ID: 10949162
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic effects of novel non-peptide chlorobenzhydryl piperazine compounds on contractile response to bradykinin in the guinea-pig ileum.
Kam YL; Ro JY; Kim HJ; Choo HY
Eur J Pharmacol; 2005 Oct; 523(1-3):143-50. PubMed ID: 16226247
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
18. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
19. Boc-lysinated-betulonic acid: a potent, anti-prostate cancer agent.
Saxena BB; Zhu L; Hao M; Kisilis E; Katdare M; Oktem O; Bomshteyn A; Rathnam P
Bioorg Med Chem; 2006 Sep; 14(18):6349-58. PubMed ID: 16777417
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]